Skip to content
DataLookout
Menu

K2SPIRITNCT06646978

Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Risk of second primary malignancies (SPM)
Timeframe: Through study completion, an average of 20 years

Secondary (1)

Treatment strategies for CML and SPM at their occurrence

Arms and interventions

Patients with chronic myeloid leukaemia included in the French imatinib-based SPIRIT trial

Drugs: Imatinib (STI571)

Sites

1 site in 1 country

  • CHU de PoitiersPoitiers, France